Resources to help patients manage out-of-pocket expenses for LENVIMA®, including information about the Eisai Assistance Program and the LENVIMA® Patient Assistance Program.
The Eisai Assistance Program offers information about patients’ benefits for LENVIMA® and available financial assistance options. Our specialists will complete a full benefit investigation to understand patients’ insurance coverage for LENVIMA®. If needed, our specialists can also discuss options for financial assistance to help patients access LENVIMA®.
With the LENVIMA® $0 Co-Pay Program, eligible commercially insured patients will pay as little as a $0 out-of-pocket for each prescription. Eisai will pay up to a maximum of $40,000 per year to assist with the out-of-pocket costs for LENVIMA®. Depending on the insurance plan, a patient could have additional financial responsibility for any amounts over Eisai’s maximum liability.
Eligibility criteria: Good toward the purchase of LENVIMA® prescriptions. The LENVIMA® $0 Co-pay Program provides up to a maximum of $40,000 per year to assist with the out-of-pocket costs for LENVIMA®. Depending on the insurance plan, a patient could have additional financial responsibility for any amounts over Eisai’s maximum liability. No substitutions permitted. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance. Not valid for LENVIMA® prescriptions reimbursed in full by any third-party payer. Save this information for reuse with each prescription. May not be combined with any other discount or offer. Program is not valid for cash paying customers. Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. You must be 18 years or older to use this card for yourself or a minor. Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the program and complying with any other conditions imposed by insurance carriers, third-party payers, and applicable law on the redemption. The value of this program is not contingent on any prior or future purchases. This card may not be accepted at all pharmacies. This card is not an insurance program. No membership fees. This offer will expire March 31, 2022.
There may be times that you need to dose reduce a patient during the course of LENVIMA® treatment due to adverse reaction before the patient has finished their current supply of LENVIMA®. Through the LENVIMA® Dose Exchange Program, eligible patients that require a dose reduction can exchange up to 15 unused doses for the same number of doses at the reduced dose strength at no additional cost.
The program allows patients to exchange unused 20-mg doses for 14-mg doses when the HCP has directed a dose reduction based on the prescribing information.
Please complete the LENVIMA® Dose Exchange enrollment form and fax—along with a prescription—to Sonexus at 855-246-5192.
Eisai has established the Patient Assistance Program for patients who need help paying for LENVIMA®. This program provides LENVIMA® at no cost to uninsured and financially burdened patients who meet the program eligibility criteria.
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
LENVIMA is indicated:
For more information about LENVIMA please see available full Prescribing Information.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.
LENVIMA® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.